X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

DuPont Brings Science-backed Quality and Innovation to Asia’s Pharmaceutical Industry at CPhI China 2020

Content Team by Content Team
14th December 2020
in Press Statements
DuPont Brings Science-backed Quality and Innovation to Asia's Pharmaceutical Industry at CPhI China 2020

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

DuPont Nutrition & Biosciences (DuPont) will use insights to help manufacturers evolve with the biggest trends in the Asia pharma industry, with highlights to the latest offerings at CPhI China 2020 from December 16–18. Attendees who visit DuPont booth E3D26 will get an exclusive look at solutions to many of the industry’s most pressing challenges, including taste-masking for pediatric medicines, pharmaceutical ingredients for acid reflux, and controlled release solutions that can significantly enhance manufacturing processes and much more.

DuPont has continuously supported its pharmaceutical customers with its vital expertise, and broad, unique portfolio that helps formulators succeed in manufacturing, regulatory, product design and beyond. As China’s pharmaceutical industry continues to expand in profitability and regulatory complexity, DuPont intends to show customers that it has the products and technical know-how to help them keep pace. 

Experts will be available to discuss the offerings which include:

  • Ensuring compliance among younger patients. No child likes the taste of medicine, which means taste-masking bitter active pharmaceutical ingredients (APIs) is of utmost importance in pediatric care. DuPont offers several solutions, including colloidal Avicel® microcrystalline cellulose (MCC), which is ideal for use in oral suspension; and ETHOCEL™ and Aquacoat®, two superior coating polymers that effectively mask unpleasant tastes.
  • Optimal ingredients for controlled release. METHOCEL™ DC2 is a cellulose ether that achieves superior process control with fewer production steps and less waste. With improved flow, faster and consistent tableting speeds, it greatly enhances overall production efficiency.
  • Sustainable ingredients that treat acid reflux. Protanal® is a tailored innovative solution highly aligned with market trends and can be used as an API in the treatment of acid reflux. Using a patented and environmentally friendly technology, this brown seaweed extract helps to enable enhanced performance.
  • Focus on quality beyond manufacturing. Given quality is paramount for our industry, DuPont will discuss its efforts to broaden its quality focus beyond manufacturing to an organizational priority. Efforts also include an extension of its renowned Avicel® to reduce technically unavoidable particles (TUPs).
  • A whole new range of innovative delivery forms for dietary supplements industry. We offer a vast range of functional ingredients that works well with nutritional ingredients to make a product that meets consumer demands – from clean label, plant-based, consumer-friendly capsules, great tasting gummies and smaller tablets for consumer convenience. Our SeaGel® vegetarian softgel technology outperforms its animal-based counterpart, imparting excellent thermal stability and implementing seamlessly into soft capsule equipment.

At the booth, attendees can attend mini talks and discuss with DuPont experts on how they can enable their goals in the pharma and dietary supplements space, including sharing of best practices for each ingredient, application expertise and regulatory knowledge tailored to the Asian market.

“All of these offerings represent our commitment to delivering strategic, high quality customer service to the Asia’s pharma industry,” explained Frank Zhao, Sales Leader, APAC, Pharma Solutions, DuPont Nutrition & Biosciences. “It’s a reflection of our global implementation of Big Q—a Quality culture. We believe our focus on quality will resonate with visitors at CPhI China, who will come away with practical solutions to create viable pharmaceutical products for this expanding market.”

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities.

About DuPont

DuPont is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety.

Previous Post

AstraZeneca and J&J COVID-19 Shots Crucial To Meet US Vaccination Goal

Next Post

Thermo Fisher Expands Clinical Supply Services in Europe

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Next Post
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

Thermo Fisher Expands Clinical Supply Services in Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In